2013 New compounds against Chagas and Leishmania
The University has developed a new family of compounds with antiparasitic properties, that are more stable, less toxic and cheaper for production compared to current drug compounds.
A new family of compounds with antiparasitic properties. These compounds are more stable, less toxic and cheaper to produce than the drugs currently used. Companies in the pharmaceutical or the veterinary sector interested in a patent license or in a research or technical cooperation agreement for developing and validating the product as antiparasitic are being sought.
As a result of the multidisciplinary cooperation between chemical and parasitologist researchers of two Spanish universities, a new family of aminosquaramide compounds with demonstrated in vivo activity against Chagas and Leshmania diseases has been developed. The chemical stability of these compounds together with the use of affordable starting products, and the lack of synthetic complexity put amino squaramides in the pole position toward the development of true low cost anti-parasitic agents. The main application of the technology is a pharmaceutical composition for the treatment of human/animal parasitic diseases.
- Notable antiparasitic activity
- New structure based on squaramide
- Good bioaviabilidad
- Low toxicity in front of Vero cells
- High effectivity ratios against the epimastigote and amastigote forms of the parasites
- Remarkable decrease (>97%) in the reactivation of parasitemia in the chronic phase after immunosuppression in mice and their chemical stability
- Affordable starting materials
- Straightforward synthesis
In vitro studies have been conducted with intra and extracellular forms of parasites, and the results have been positive. Currently, under development: studies in animal models (mice). This new family is protected by a patent.